Stephen Liu, MD, discusses common NRG1 fusion partners in patients with non–small cell lung cancer.
Stephen Liu, MD, an associate professor of medicine, director of thoracic oncology, and director of developmental therapeutics at Georgetown Lombardi Comprehensive Cancer Center, discusses common NRG1 fusion partners in patients with non–small cell lung cancer (NSCLC).
The most common fusion partner in NSCLC is CD74, as indicated by multiple studies, Liu says. Additionally, several other fusion partners have been identified such as SLC3A2, SDC4, and RBPMS. Previous findings have reported almost 20 NRG1 fusion partners, he explains.
Looking forward, experts in the field are seeking to understand the impact of fusion partners on the underlying disease biology and if they could guide treatment decisions. Currently, this impact is not understood, Liu concludes.